Coherus BioSciences Inc
For the period ended Dec 31, 2023. Filed Mar 15, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 15, 2024
CHRS$0.82+6.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Loss
(in thousands)
| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| · · Year Ended December 31, | |||||||||
| · 2023 · 2022 · 2021 | |||||||||
| Net loss | | $(237,892) | | | (291,754) | | $(287,100) | ||
| Other comprehensive income (loss): | | | | | | ||||
| Unrealized gain on available-for-sale securities, net of tax | | | 2 | | | 22 | | | — |
| Foreign currency translation adjustments, net of tax | | (1) | | (1) | | — | |||
| Comprehensive loss | | $(237,891) | | $(291,733) | | $(287,100) | |||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.